Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 19/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24086095 | 0.88 | ERN1 (0.74) | ERN1 | |
| SCHEMBL29682880 | 0.88 | ERN1 (0.74) | ERN1 | |
| SCHEMBL6644760 | 0.85 | ESR1 (0.63) | ERN1 | |
| SCHEMBL5734552 | 0.85 | ERN1 (0.47) | ERN1ALDH1A1MAPT | |
| SCHEMBL6640732 | 0.84 | ERN1 (0.70) | ERN1 | |
| SCHEMBL6644485 | 0.84 | ERN1 (0.62) | ERN1 | |
| SCHEMBL30554383 | 0.84 | ERN1 (0.69) | ERN1 | |
| SCHEMBL26606756 | 0.84 | ERN1 (0.69) | ERN1 | |
| SCHEMBL29751505 | 0.84 | ERN1 (0.69) | ERN1 | |
| SCHEMBL30554384 | 0.84 | ERN1 (0.69) | ERN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11569461-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2023-01-31 | — | — | US | disclosed |
| US-20190181358-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANOMETALLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | LAPTO CO., LTD. (KR) | 2019-06-13 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| US-8629147-B2 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION (US) | 2014-01-14 | — | — | US | disclosed |
| EP-2298770-A1 | Heterocyclic compounds as TrkA modulators | ChemBridge Corporation (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20100152455-A1 | ORGANOMETALIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | GRACEL DISPLAY INC. (KR) | 2010-06-17 | — | — | US | disclosed |
| CN-101641423-A | Organometallic compound for electroluminescence and organic electroluminescent device using the same | GRACEL DISPLAY INC KR | 2010-02-03 | — | — | CN | disclosed |
| EP-2092040-A1 | ORGANOMETALIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMIESCENT DEVICE USING THE SAME | Gracel Display Inc. (KR) | 2009-08-26 | — | — | EP | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | CHEMBRIDGE CORPORATION | 2008-08-28 | — | — | US | disclosed |
| WO-2008082249-A1 | ORGANOMETALIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMIESCENT DEVICE USING THE SAME | GRACEL DISPLAY INC. (KR) | 2008-07-10 | — | — | WO | disclosed |
| WO-2007056155-A1 | HETEROCYCLIC COMPOUNDS AS TYROSINE KINASE MODULATORS | CHEMBRIDGE RESEARCH LABORATORIES, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
| EP-1412327-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG Biomedical Institute (US) | 2004-04-28 | — | — | EP | disclosed |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-11-06 | — | — | US | disclosed |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | LG BIOMEDICAL INSTITUTE | 2003-10-02 | — | — | US | disclosed |
| WO-2002096867-A2 | INHIBITORS OF PROTEIN KINASE FOR THE TREATMENT OF DISEASE | LG BIOMEDICAL INSTITUTE (US) | 2002-12-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152455-A1 | ORGANOMETALIC COMPOUNDS FOR ELECTROLUMINESCENCE AND ORGANIC ELECTROLUMINESCENT DEVICE USING THE SAME | EPCAM, ORC3, L1CAM | ERN1 4021/4885ALDH1A1 911/4885MAPT 2662/4885 |
| US-11569461-B2 | Organic electroluminescence device and organometallic compound for organic electroluminescence device | CHRM1, L1CAM, CHRM4 | ERN1 505/4885ALDH1A1 451/4885MAPT 1819/4885 |
| US-20190181358-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND ORGANOMETALLIC COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | CHRM1, L1CAM, CHRM4 | ERN1 505/4885ALDH1A1 451/4885MAPT 1819/4885 |
| US-20030208067-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885ALDH1A1 3678/4885MAPT 1057/4885 |
| US-20030187007-A1 | Inhibitors of protein kinase for the treatment of disease | MAP3K20, MAP3K1, MAP3K2 | ERN1 446/4885ALDH1A1 3678/4885MAPT 1057/4885 |
| US-20080207635-A1 | Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders | LCK, MALT1, MYD88 | ERN1 1996/4885ALDH1A1 2293/4885MAPT 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.